Dimenhydrinate

DRUG INFORMATION

  ADULT
    - Adults Nausea or vomiting may be expected to be controlled for approximately 4
      hours with 50 mg, and prevented by a similar dose every 4 hours.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'dosage and
      administration', retrieved 2026-08-29
    - Its administration may be attended by some degree of drowsiness in some patients,
      and 100 mg every 4 hours may be given in conditions in which drowsiness is not
      objectionable or is even desirable.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'dosage and
      administration', retrieved 2026-08-29
    - For intramuscular administration, each milliliter (50 mg) of solution is injected
      as needed, but for intravenous administration, each milliliter (50 mg) of solution
      must be diluted in 10 mL of 0.9% Sodium Chloride Injection, USP and injected over
      a period of 2 minutes.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Dimenhydrinate in the injectable form is indicated when the oral form is
      impractical. Adults Nausea or vomiting may be expected to be controlled for
      approximately 4 hours with 50 mg, and prevented by a similar dose every 4 hours.
      Its administration may be attended by some degree of drowsiness in some patients,
      and 100 mg every 4 hours may be given in conditions in which drowsiness is not
      objectionable or is even desirable.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'dosage and
      administration', retrieved 2026-08-29
    - Pediatric For intramuscular administration, 1.25 mg/kg of body weight or 37.5 mg/m
      2 of body surface area is administered four times daily. The maximum dose should
      not exceed 300 mg daily (see CONTRAINDICATIONS ). Parenteral drug products should
      be inspected visually for particulate matter and discoloration prior to
      administration, whenever solution and container permit.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'dosage and
      administration', retrieved 2026-08-29
    - Pediatric For intramuscular administration, 1.25 mg/kg of body weight or 37.5 mg/m
      2 of body surface area is administered four times daily.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for dimenhydrinate
      (Dimenhydrinate), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for dimenhydrinate
      (Dimenhydrinate), retrieved 2026-08-29

  PREGNANCY
    - Reproduction studies have been performed in rats at doses up to 20 times the human
      dose, and in rabbits at doses up to 25 times the human dose (on a mg/kg basis),
      and have revealed no evidence of impaired fertility or harm to the fetus due to
      dimenhydrinate.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'pregnancy',
      retrieved 2026-08-29
    - There are no adequate and well-controlled studies in pregnant women.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'pregnancy',
      retrieved 2026-08-29
    - However, clinical studies in pregnant women have not indicated that dimenhydrinate
      increases the risk of abnormalities when administered in any trimester of
      pregnancy.
      Source: US FDA label for dimenhydrinate (Dimenhydrinate), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Nothing on breastfeeding in this label. Treat as unknown, not as safe.
      Source: Read and found silent: the US FDA label for dimenhydrinate
      (Dimenhydrinate), retrieved 2026-08-29